Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis - Report - MDSpire

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • By

  • Enrique Gómez de la Fuente

  • Enrique Herrera

  • Iñigo Martinez-Espronceda Esquerdo

  • David Vidal Sarró

  • Ignasi Figueras-Nart

  • Juan F. Silvestre Salvador

  • Yolanda Gilaberte

  • Sergio Santos Alarcón

  • Esther Serra-Baldrich

  • Monica Munera Campos

  • Rosa M. Moro

  • Silvia Díaz-Cerezo

  • Sebastian Moyano

  • Irene Talavera-Rodríguez

  • Mercedes Núñez

  • April 21, 2026

  • 0 min

Share

Clinical Report: Evaluation of Baricitinib for Atopic Dermatitis Patients in Spain

Overview

The DAMA-S study evaluated baricitinib's effectiveness and persistence in treating moderate-to-severe atopic dermatitis (AD) in Spain. Results indicated high treatment persistence and significant improvements in skin severity scores among patients who remained on therapy.

Background

Atopic dermatitis is a chronic inflammatory skin disorder that significantly impacts patients' quality of life due to symptoms like intense pruritus and psychological distress. The introduction of baricitinib, a selective JAK1/JAK2 inhibitor, provides a new systemic treatment option for patients with moderate-to-severe AD. Understanding real-world treatment patterns and effectiveness is crucial for optimizing patient care in this population.

Data Highlights

Time Point (Weeks)Persistence (%)EASI75 (%)IGA 0 or 1 (%)
1685.169.779.3
2475.765.463.6
5258.4N/AN/A

Key Findings

  • Baricitinib persistence rates were 85.1%, 75.7%, and 58.4% at weeks 16, 24, and 52, respectively.
  • By week 16, 69.7% of patients achieved a ≥ 75% improvement in EASI (EASI75).
  • 79.3% of patients reached an IGA score of 0 or 1 by week 16.
  • Effectiveness of baricitinib was demonstrated in routine clinical practice among patients who remained on treatment.
  • The study highlights the importance of real-world evidence in understanding treatment outcomes for AD.

Clinical Implications

The findings suggest that baricitinib is an effective treatment option for patients with moderate-to-severe atopic dermatitis, with high persistence rates indicating good tolerability in a real-world setting. Clinicians should consider baricitinib as a viable systemic therapy, particularly for patients who do not respond adequately to topical treatments.

Conclusion

Baricitinib demonstrates significant effectiveness and persistence in treating moderate-to-severe atopic dermatitis in Spain, reinforcing its role as a key therapeutic option in clinical practice.

References

  1. Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review | Dermatology and Therapy | Springer Nature, 2023 -- Results from the DAMA-S study
  2. European Guideline (EuroGuiDerm) on atopic eczema: Living update - PubMed, 2025 -- Current guidelines on systemic treatments for AD
  3. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials - PubMed, 2020 -- Efficacy and safety of baricitinib
  4. Clinical Rheumatology — A Comparative Study of Baricitinib Versus TNF-α Inhibitors and Conventional DMARDs in Egyptian Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
  5. Clinical Rheumatology — Progression of Structural Joint Damage in Early Rheumatoid Arthritis Patients Undergoing Treatment with Methotrexate, Baricitinib, or Combination Therapy: Insights from the Phase 3 RA-BEGIN Trial Based on Clinical Outcomes
  6. Clinical Rheumatology — Evaluating the Role of Early Therapeutic Drug Monitoring of Adalimumab in Predicting Treatment Outcomes and Immunogenicity in Rheumatic Disorders
  7. Clinical Rheumatology — Economic Evaluation of Tofacitinib Treatment Sequences for Rheumatoid Arthritis Management in Spain
  8. European Guideline (EuroGuiDerm) on atopic eczema: Living update - PubMed
  9. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials - PubMed
  10. Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review | Dermatology and Therapy | Springer Nature Link

Original Source(s)

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, Rosa M. Moro, Silvia Díaz-Cerezo, Sebastian Moyano, Irene Talavera-Rodríguez, Mercedes Núñez

  • April 21, 2026

Related Content

Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

Maternal Gestational Diabetes Mellitus Linked to Elevated Risk of Atopic Dermatitis in Offspring: Insights from a National Retrospective Cohort Study Analyzing Treatment Approaches